{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:37:17Z","timestamp":1780915037230,"version":"3.54.1"},"reference-count":104,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["2319\u201019"],"award-info":[{"award-number":["2319\u201019"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Greater understanding of the mechanisms involved in the disease progression of haematological malignancies has led to the introduction of novel targeted therapies with reduced toxicity compared with chemotherapy\u2010based regimens, which has expanded the treatment options for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL). Ibrutinib is a first\u2010in\u2010class Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of patients with CLL\/SLL or relapsed\/refractory MCL. However, next\u2010generation BTK inhibitors have been developed with improved specificity and the potential to reduce the off\u2010target toxicity observed with ibrutinib. Acalabrutinib is a highly selective, next\u2010generation BTK inhibitor, which was granted accelerated approval by the US Food and Drug Administration in 2017 for the treatment of adult patients with MCL who have received at least one prior therapy. In November 2019, it was also granted approval for the treatment of adult patients with CLL\/SLL on the basis of two phase 3 clinical trials. This review describes the current understanding of acalabrutinib according to clinical study data for the treatment of MCL and CLL\/SLL and shares recommendations from our practice on how it should be used when treating patients in the clinic, including dosing, administration and management of adverse events.<\/jats:p>","DOI":"10.1111\/bjh.17184","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T06:38:18Z","timestamp":1605940698000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Incorporating acalabrutinib, a selective next\u2010generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies"],"prefix":"10.1111","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey V.","family":"Danilov","sequence":"first","affiliation":[{"name":"City of Hope National Medical Center Duarte CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3483-2142","authenticated-orcid":false,"given":"Daniel O.","family":"Persky","sequence":"additional","affiliation":[{"name":"The University of Arizona Cancer Center Tucson AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2004.00489.x"},{"key":"e_1_2_8_4_1","unstructured":"American Cancer Society.Key statistics for chronic lymphocytic leukemia.https:\/\/www.cancer.org\/cancer\/chronic\u2010lymphocytic\u2010leukemia\/about\/key\u2010statistics.html(2020 accessed March 3 2020)."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-764373"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31328"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-873083"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.s.034"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_8_13_1","first-page":"646","article-title":"High\u2010dose cytarabine in mantle cell lymphoma","volume":"13","author":"Martin P","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-791392"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.14122.1"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2017.07.006"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.664797"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2011.585971"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00741.x"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1006\/smim.1998.0123"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.329"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.65"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141018"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1589"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0807082"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810044"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-603670"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2438_98"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.06.004"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171041"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13651"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-742437"},{"key":"e_1_2_8_44_1","unstructured":"IMBRUVICA\u00ae (ibrutinib) [prescribing information].Pharmacyclics.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/205552s026 210563s002lbl.pdf(2019 accessed 14 August 2019)."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31554"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_2_8_47_1","unstructured":"AstraZeneca Pharmaceuticals LP.Calquence approved in the US for adult patients with chronic lymphocytic leukaemia.https:\/\/www.astrazeneca.com\/media\u2010centre\/press\u2010releases\/2019\/calquence\u2010approved\u2010in\u2010the\u2010us\u2010for\u2010adult\u2010patients\u2010with\u2010chronic\u2010lymphocytic\u2010leukaemia\u201021112019.html(2019 accessed 14 August 2020)."},{"key":"e_1_2_8_48_1","unstructured":"AstraZeneca Pharmaceuticals LP.Calquence showed promising clinical improvement in majority of 19 hospitalised COVID\u201019 patients.https:\/\/www.astrazeneca.com\/media\u2010centre\/press\u2010releases\/2020\/calquence\u2010showed\u2010promising\u2010clinical\u2010improvement\u2010in\u2010majority\u2010of\u201019\u2010hospitalised\u2010covid\u201019\u2010patients.html#:~:text=In%20the%20US%2C%20Australia%2C%20the and%20in%20Canada%20for%20CLL(2020 accessed 14 August 2020)."},{"key":"e_1_2_8_49_1","unstructured":"BRUKINSA\u2122 (zanubrutinib) [prescribing information].BeiGene Ltd.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/213217s000lbl.pdf(2019 accessed 10 January 2020)."},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.832.832"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001160"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8007"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-2596"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-109973"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1446"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011999"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-808808"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159607"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2920.2920"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-2624"},{"key":"e_1_2_8_65_1","article-title":"Nonclinical safety evaluation of acalabrutinib, a selective covalent inhibitor of Bruton tyrosine kinase (BTK)","volume":"162","author":"Mookherjee P","year":"2018","journal-title":"Toxicologist"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110327"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0575-9"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110451"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007"},{"key":"e_1_2_8_71_1","article-title":"Phase 2 study of acalabrutinib in ibrutinib\u2010intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","author":"Rogers KA","year":"2019","journal-title":"Eur Hematol Assoc Library"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130062"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1130"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128404"},{"key":"e_1_2_8_75_1","unstructured":"GhiaP PlutaA WachM LysakD KozakT SimkovicT et al.ASCEND Phase 3 study of acalabrutinib vs. investigator's choice of rituxiumab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukaemia (CLL). In:Proceedings of the European Hematology Association Annual Meeting; 2019 June 16; Amsterdam. EHA Library:2019;LB2606.https:\/\/library.ehaweb.org\/eha\/2019\/24th\/273259\/paolo.ghia.ascend.phase.3.study.of.acalabrutinib.vs.investigators.choice.of.html(2020 accessed 5 March 2020)."},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30210-8"},{"key":"e_1_2_8_77_1","unstructured":"NCCN.Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma vol 3.2020. \u00a9 National Comprehensive Cancer Network Inc. 2020. All rights reserved.https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx(2020 accessed 5 March 2020)."},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124631"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001883"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-764712"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-846808"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15690"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2018.06.018"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.8581"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2017.01.004"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12408"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.156"},{"key":"e_1_2_8_88_1","first-page":"4996","article-title":"CYP3A\u2010Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib","volume":"130","author":"Izumi R","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_89_1","unstructured":"CALQUENCE\u00ae (acalabrutinib) [prescribing information].AstraZeneca Pharmaceuticals LP.https:\/\/www.azpicentral.com\/calquence\/calquence.pdf(2019 accessed10 January 2020)."},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7521"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_8_92_1","first-page":"4326","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies","volume":"130","author":"Byrd JC","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00354"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2437"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.164285"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13042"},{"key":"e_1_2_8_97_1","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1182\/blood-2019-123057","article-title":"A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation","volume":"134","author":"Brown JR","year":"2019","journal-title":"Blood"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15784"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127506"},{"key":"e_1_2_8_100_1","unstructured":"CALQUENCE\u00ae (acalabrutinib) [prescribing information].AstraZeneca Pharmaceuticals LP.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/210259s000lbl.pdf(2017 accessed 10 January 2020)."},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.8032"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3504"},{"key":"e_1_2_8_105_1","doi-asserted-by":"crossref","first-page":"C186","DOI":"10.1158\/1535-7163.TARG-15-C186","article-title":"Abstract C186: SNS\u2010062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation","volume":"14","author":"Binnerts ME","year":"2015","journal-title":"Mol Cancer Ther"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17184","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17184","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:28:15Z","timestamp":1693567695000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/bjh.17184"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17184","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"2020-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}